Quick Takeaways
- PMCB - PharmaCyte Biotech, Inc. has 15 insiders with reported activity on this page.
- Net insider value flow over the last year: +$128,708.
- Recent transaction rows are available for direct filing-level review.
- Info
- Significant Ownership
- Insider Ownership
- Insider Trading
- Financials
Insider Transactions Reported by 15 Insiders of PharmaCyte Biotech, Inc.
- Symbol
- PMCB on Nasdaq
- Location
- Las Vegas, NV
What Changed
- Buy value: $128,708; sell value: $0.
- Net share flow: +160,000.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Source Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsNet insider flow leans to buying over the last 12 months. Net value: +$128,708.
Buys
$128,708
Shares: 160,000
Insiders: 2
Sells
$0
Shares: 0
Insiders: 0
Net
+$128,708
Shares: +160,000
Insiders: 2
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 160,000 | 0 | $128,708 | $0 | +$128,708 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
PharmaCyte Biotech, Inc. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Joshua Silverman | CEO and President, Director | $397,694 | +$80,476 | +25% | Mixed | 05 Jan 2026 |
| Jonathan Schechter | Director | $162,393 | +$48,232 | +42% | Filing P/S | 31 Mar 2026 |
| Robert Weinstein | Director | $42,075 | Mixed | 31 Mar 2026 | ||
| Michael M. Abecassis | Director | $23,417 | Mixed | 31 Mar 2026 | ||
| Wayne R. Walker | Director | $21,037 | Mixed | 31 Mar 2026 | ||
| Carlos A. Trujillo | Chief Financial Officer, Director | Mixed | 20 Nov 2023 | |||
| Matthias Loehr | Director | Mixed | 31 Mar 2022 | |||
| Daniel Stuart Farb | Director | Mixed | 28 Dec 2022 | |||
| Daniel Allen | Director | Mixed | 28 Dec 2022 | |||
| Gerald W. Crabtree | Chief Science Officer, Director | Mixed | 10 Aug 2021 | |||
| Thomas C. K. Yuen | Director | Mixed | 10 Aug 2021 | |||
| Jack E. Stover | Director | Mixed | 15 Aug 2022 | |||
| Thomas Liquard | Director | Mixed | 10 Aug 2021 | |||
| Kenneth L. Waggoner | Chairman, CEO, Pres and GC, Director | Mixed | 10 Aug 2021 | |||
| Raymond Cf Tong | Director | Mixed | 10 Aug 2021 |
Top shareholders of PharmaCyte Biotech, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Ayrton Capital LLC |
13D/G
|
— |
9.9%
|
774,100
|
$967,625 | $0 | 31 Dec 2024 | |
| INTRACOASTAL CAPITAL, LLC |
13D/G
|
Mitchell P. Kopin |
5%
|
532,254
|
$484,351 | $0 | 31 Dec 2025 | |
| Joshua Silverman |
3/4/5
|
CEO and President, Director |
4.4%
|
466,250
|
$397,694 | +$80,476 | 05 Jan 2026 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
2.2%
|
229,722
|
$166,319 | — | 31 Dec 2025 | |
| Jonathan Schechter |
3/4/5
|
Director |
—
mixed-class rows
|
311,670
mixed-class rows
|
$162,393 | +$48,232 | 31 Mar 2026 | |
| HRT FINANCIAL LP |
13F
|
Company |
1.7%
|
182,801
|
$132,000 | — | 31 Dec 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.2%
|
123,844
|
$89,672 | — | 31 Dec 2025 | |
| SABBY MANAGEMENT, LLC |
13F
|
Company |
0.94%
|
100,000
|
$72,400 | — | 31 Dec 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.88%
|
94,036
|
$68,082 | — | 31 Dec 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.7%
|
74,919
|
$54,241 | — | 31 Dec 2025 | |
| Robert Weinstein |
3/4/5
|
Director |
—
mixed-class rows
|
160,420
mixed-class rows
|
$42,075 | — | 31 Mar 2026 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.33%
|
35,601
|
$25,775 | — | 31 Dec 2025 | |
| Michael M. Abecassis |
3/4/5
|
Director |
—
mixed-class rows
|
142,262
mixed-class rows
|
$23,417 | — | 31 Mar 2026 | |
| Wayne R. Walker |
3/4/5
|
Director |
—
mixed-class rows
|
139,795
mixed-class rows
|
$21,037 | — | 31 Mar 2026 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
0.25%
|
26,178
|
$18,952 | — | 31 Dec 2025 | |
| SIMPLEX TRADING, LLC |
13F
|
Company |
0.24%
|
25,834
|
$18,703 | — | 31 Dec 2025 | |
| TWO SIGMA SECURITIES, LLC |
13F
|
Company |
0.23%
|
24,553
|
$17,776 | — | 31 Dec 2025 | |
| XTX Topco Ltd |
13F
|
Company |
0.23%
|
24,442
|
$17,696 | — | 31 Dec 2025 | |
| EQUITEC PROPRIETARY MARKETS, LLC |
13F
|
Company |
0.21%
|
22,227
|
$16,092 | — | 31 Dec 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.11%
|
11,391
|
$8,247 | — | 31 Dec 2025 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.05%
|
4,898
|
$3,546 | — | 31 Dec 2025 | |
| UBS Group AG |
13F
|
Company |
0.03%
|
2,746
|
$1,988 | — | 31 Dec 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
314
|
$227 | — | 31 Dec 2025 | |
| OSAIC HOLDINGS, INC. |
13F
|
Company |
0%
|
303
|
$219 | — | 31 Dec 2025 | |
| Sachetta, LLC |
13F
|
Company |
0%
|
14
|
$11 | — | 31 Dec 2025 | |
| Aviso Financial Inc. |
13F
|
Company |
0%
|
12
|
$8 | — | 31 Dec 2025 | |
| BFSG, LLC |
13F
|
Company |
0%
|
5
|
$4 | — | 31 Dec 2025 | |
| FINANCIAL CONSULATE, INC |
13F
|
Company |
0%
|
2
|
$2 | — | 31 Dec 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0%
|
2
|
$2 | — | 31 Dec 2025 | |
| CALDWELL SUTTER CAPITAL, INC. |
13F
|
Company |
—
class O/S missing
|
2
|
$1 | — | 31 Dec 2025 | |
| NewEdge Advisors, LLC |
13F
|
Company |
0%
|
2
|
$1 | — | 31 Dec 2025 | |
| BlackRock, Inc. |
13F
|
Company |
0%
|
1
|
$1 | — | 31 Dec 2025 | |
| IFP Advisors, Inc |
13F
|
Company |
0%
|
1
|
$1 | — | 31 Dec 2025 | |
| MCF Advisors LLC |
13F
|
Company |
0%
|
1
|
$1 | — | 31 Dec 2025 | |
| Daniel Allen |
3/4/5
|
Director |
—
class O/S missing
|
125,000
|
— | — | 28 Dec 2022 | |
| Daniel Stuart Farb |
3/4/5
|
Director |
—
class O/S missing
|
125,000
|
— | — | 28 Dec 2022 | |
| Carlos A. Trujillo |
3/4/5
|
Chief Financial Officer, Director |
—
class O/S missing
|
85,000
|
— | — | 20 Nov 2023 | |
| Kenneth L. Waggoner |
3/4/5
|
Chairman, CEO, Pres and GC, Director |
—
class O/S missing
|
20,600
|
— | — | 10 Aug 2021 | |
| Gerald W. Crabtree |
3/4/5
|
Chief Science Officer, Director |
—
class O/S missing
|
11,200
|
— | — | 10 Aug 2021 | |
| Matthias Loehr |
3/4/5
|
Director |
—
class O/S missing
|
3,004
|
— | — | 31 Mar 2022 | |
| Thomas C. K. Yuen |
3/4/5
|
Director |
—
class O/S missing
|
1,667
|
— | — | 10 Aug 2021 | |
| Thomas Liquard |
3/4/5
|
Director |
—
class O/S missing
|
1,667
|
— | — | 10 Aug 2021 | |
| Raymond Cf Tong |
3/4/5
|
Director |
—
class O/S missing
|
1,333
|
— | — | 10 Aug 2021 |
Recent Insider Transactions by Companies or Individuals for PharmaCyte Biotech, Inc.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Robert Weinstein | PMCB | Stock Option (Right to Buy) | Award | 119,170 | 119,170 | 31 Mar 2026 | Direct | |||
| Wayne R. Walker | PMCB | Stock Option (Right to Buy) | Award | 119,170 | 119,170 | 31 Mar 2026 | Direct | |||
| Jonathan Schechter | PMCB | Stock Option (Right to Buy) | Award | 119,170 | 119,170 | 31 Mar 2026 | Direct | |||
| Michael M. Abecassis | PMCB | Stock Option (Right to Buy) | Award | 119,170 | 119,170 | 31 Mar 2026 | Direct | |||
| Joshua N. Silverman | PMCB | Common Stock | Purchase | 10.6% | $33,316 | $0.8329 | 40,000 | 416,250 | 07 Jan 2026 | Direct |
| Jonathan Schechter | PMCB | Common Stock | Purchase | 11.6% | $16,872 | $0.8436 | 20,000 | 192,500 | 07 Jan 2026 | Direct |
| Joshua N. Silverman | PMCB | Common Stock | Purchase | 8.66% | $23,667 | $0.7889 | 30,000 | 376,250 | 06 Jan 2026 | Direct |
| Jonathan Schechter | PMCB | Common Stock | Purchase | 13.1% | $15,808 | $0.7904 | 20,000 | 172,500 | 06 Jan 2026 | Direct |
| Joshua N. Silverman | PMCB | Common Stock | Purchase | 9.49% | $23,493 | $0.7831 | 30,000 | 346,250 | 05 Jan 2026 | Direct |
| Jonathan Schechter | PMCB | Common Stock | Purchase | 15.1% | $15,552 | $0.7776 | 20,000 | 152,500 | 05 Jan 2026 | Direct |
| Robert Weinstein | PMCB | Common Stock | Tax liability | -45% | -33,750 | 41,250 | 12 Dec 2025 | Direct | ||
| Robert Weinstein | PMCB | Common Stock | Award | 75,000 | 75,000 | 12 Dec 2025 | Direct | |||
| Wayne R. Walker | PMCB | Common Stock | Tax liability | -45% | -16,875 | 20,625 | 12 Dec 2025 | Direct | ||
| Wayne R. Walker | PMCB | Common Stock | Award | 37,500 | 37,500 | 12 Dec 2025 | Direct | |||
| Joshua N. Silverman | PMCB | Common Stock | Tax liability | -45% | -258,750 | 316,250 | 12 Dec 2025 | Direct | ||
| Joshua N. Silverman | PMCB | Common Stock | Award | 575,000 | 575,000 | 12 Dec 2025 | Direct | |||
| Jonathan Schechter | PMCB | Common Stock | Tax liability | -33.8% | -67,500 | 132,500 | 12 Dec 2025 | Direct | ||
| Jonathan Schechter | PMCB | Common Stock | Award | 300% | 150,000 | 200,000 | 12 Dec 2025 | Direct | ||
| Michael M. Abecassis | PMCB | Common Stock | Tax liability | -43.1% | -16,875 | 22,292 | 12 Dec 2025 | Direct | ||
| Michael M. Abecassis | PMCB | Common Stock | Award | 2249.6% | 37,500 | 39,167 | 12 Dec 2025 | Direct | ||
| Robert Weinstein | PMCB | Stock Option (Right to Buy) | Award | 63,233 | 63,233 | 25 Apr 2025 | Direct | |||
| Wayne R. Walker | PMCB | Stock Option (Right to Buy) | Award | 63,233 | 63,233 | 25 Apr 2025 | Direct | |||
| Jonathan Schechter | PMCB | Stock Option (Right to Buy) | Award | 63,233 | 63,233 | 25 Apr 2025 | Direct | |||
| Michael M. Abecassis | PMCB | Stock Option (Right to Buy) | Award | 63,233 | 63,233 | 25 Apr 2025 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.